IBA Business Update – Third Quarter 2022
17 Novembre 2022 - 7:00AM
IBA Business Update – Third Quarter 2022
Louvain-La-Neuve, Belgium, 17 November
2022 - IBA (Ion Beam Applications S.A., EURONEXT), the
world leader in particle accelerator technology, today announces
its business update for the third quarter ending 30 September
2022.
Group Overview
- Business operations continue to be strong, with good
performance across all four business units
- Exceptional group order intake of EUR 260 million at 30
September for 2022 to date, compared to EUR 133 million for the
first nine months of 2021, driven by strong performance across the
business, particularly within Industrial Solutions
- Backlog remains high at EUR 1.2 billion and new tenders
continue to progress internationally for all business units
- Strong balance sheet with (unaudited) net cash position of EUR
134 million (30 June 2022: 137 million)
Olivier Legrain, Chief Executive Officer
of IBA commented: “IBA has continued to see solid
performance in the third quarter across all business units, both in
terms of contract wins, technological advances and supported by
targeted value driving acquisitions. We have been especially
pleased to see continued momentum in Industrial Solutions, with the
business unit passing a key milestone of EUR 100 million order
intake to date this year. Within proton therapy we are seeing
market dynamics shifting favorably with demand building in all
regions globally and resulting in IBA winning strategically
significant, high-value contracts. Looking ahead, whilst some
challenges remain, the strategies and investments we are making are
positively impacting and we are confident in the longer-term
performance of the Group, underpinned by a strong balance sheet
that we will continue to utilize for investment in future
growth.”
Proton Therapy
- 24 projects ongoing in Proton Therapy, with nine Proteus®PLUS1
and 15 Proteus®ONE1 systems in progress
- An active global pipeline, highlighting the strength of proton
therapy market across all geographies
- A total of 40 service contracts now generating recurring
revenues globally
- IBA qualified as the only supplier for the second round of
significant tender to provide ten proton therapy units across
Spain
- Multi-year research collaboration signed with Fred Hutchinson
Cancer Center and the University of Washington (UW), Seattle, for
ConformalFLASH®2 Proton Therapy
- Collaboration agreement signed with Apollo Hospitals Enterprise
Ltd (AHEL)
- The PROTECT-trial consortium enrolled the first patient in a
trial investigating proton therapy in oesophageal cancer
Other Accelerators (RadioPharma,
Industrial)
- Other Accelerators continued to perform strongly in Q3, with
eight new systems sold in the period. A total of 29 systems have
been sold in the first nine months of 2022, compared to 23 for the
same period last year
- Exceptional performance by Industrial Solutions, with the
business reaching the milestone of EUR 100 million order intake to
date
- Collaboration deal agreed with Chengdu New Radiomedicine
Technology Co., Ltd (CNRT) to install a Cyclone® IKON in Chengdu,
Sichuan Province, China
- Agreement signed with NorthStar Medical Radioisotopes for two
additional Rhodotron® electron beam accelerators for commercial
production of radioisotopes
- Launched Pantera, a joint venture with SCK CEN to produce
actinium-225, one of the most promising alpha-emitting
radioisotopes to fight cancers
- Contract for the installation of an integrated
radiopharmaceutical production facility in Georgia, signed
post-period end
- Post-period, contract with Sweden Ghana Medical Centre signed
for an IntegraLab® PLUS in Ghana
Dosimetry
- Signed a strategic alliance for radiation therapy dosimetry
solutions with ScandiDos A.B. (SDOS.ST) and made a minority
investment in the company
- IBA’s dosimetry solutions were made compatible with Halcyon®
and Ethos™ radiotherapy and adaptive therapy solutions, post-period
end
- Expanded IBA’s myQA® iON technology into Radiation Therapy,
post-period end
Outlook IBA has continued to
perform well across all business units in 2022 to date and this
momentum is expected to persist for the remainder of the year and
beyond. The pipeline remains highly active in all businesses,
underpinning visibility for the period ahead. Whilst some supply
chain and inflation related challenges remain, we are seeing
gradual improvements and as a business, we continue to mitigate
macroeconomic pressures. With an exceptionally strong balance
sheet, we are continuing with our extensive investment plan to
bolster our infrastructure, supply chain and logistics, reinforce
our digital ambitions and continue to maintain our market-leading
technology. Alongside this, we will look to seek value-enhancing
opportunities to drive future sustainable growth.
Financial calendar Full Year
Results
2023
23 March 2023Business Update First Quarter
2023
18 May 2023General
Assembly
14 June 2023
About IBAIBA (Ion Beam
Applications S.A.) is the world leader in particle accelerator
technology. The company is the leading supplier of equipment and
services in the field of proton therapy, considered to be the most
advanced form of radiation therapy available today. IBA is also a
leading player in the fields of industrial sterilization,
radiopharmaceuticals and dosimetry. The company, based in
Louvain-la-Neuve, Belgium, employs approximately 1,800 people
worldwide. IBA is a certified B Corporation (B Corp) meeting the
highest standards of verified social and environmental
performance.
IBA is listed on the pan-European stock exchange
EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at:
www.iba-worldwide.com
For further information, please
contact:
IBASoumya ChandramouliChief
Financial Officer+32 10 475 890Investorrelations@iba-group.com
Olivier LechienCorporate Communication
Director+32 10 475 890communication@iba-group.com
For media and investor enquiries: Consilium
Strategic Communications Amber Fennell, Angela Gray, Lucy
Featherstone +44 (0) 20 3709 5700 IBA@consilium-comms.com
1 Proteus®PLUS and Proteus®ONE are brand names of Proteus
235
2 ConformalFLASH® is a registered brand of IBA’s Proton FLASH
irradiation solution currently under research and development
phase.
- 221117-IBA-Q3-business_update-EN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024